DOH urges ivermectin recipients to report any adverse effects | Inquirer

DOH urges ivermectin recipients to report any adverse effects

By: - Reporter /
/ 01:36 PM May 01, 2021

MANILA, Philippines — The Department of Health (DOH) on Saturday called on individuals who received ivermectin pills during a distribution event in Quezon City to report to the agency any adverse effects that they may experience due to the drug.

Anakalusugan Partylist Rep. Mike Defensor and Deputy Speaker Rodante Marcoleta distributed ivermectin capsules to Quezon City residents on Thursday despite that the antiparasitic drug has yet to secure approval for human use from the Food and Drug Administration (FDA), either as treatment for COVID-19 or as prophylaxis.

Article continues after this advertisement

“Nagbigay abiso na po, and the Secretary encourages all those who received the ivermectin capsules, kung maaari, magreport lang po sa DOH para lang po malaman namin kung sakaling meron po silang ibang mararamdaman and if they need anything, handa po ang DOH tumulong,” DOH spokesperson Ma. Rosario Vergeire said in a televised briefing.

FEATURED STORIES

(We have given advice and the Secretary encourages all those who received the ivermectin capsules to report to the DOH and let us know in case they feel any side effects and if they need anything, the DOH is ready to help.)

DOH Secretary Francisco Duque III said the FDA should investigate the prescriptions provided to recipients of ivermectin. He stressed prescriptions should contain complete details of the issuing physician or medical practitioner.

While ivermectin has yet to receive approval, FDA however issued compassionate special permits to five hospitals.

EDV
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the and acknowledge that I have read the .

MOST READ
TAGS: DoH, Ivermectin, Mike Defensor

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the and acknowledge that I have read the .

© Copyright 1997-2025 | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies.